Puma Biotechnology, Inc.’s PBYI shares were up 9.1% after the company announced that its Marketing Authorization Application (MAA) for neratinib has been validated and is now under assessment by the ...
LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental ...
LOS ANGELES--Puma Biotechnology, Inc. (PBYI), a development stage biopharmaceutical company, today provided an update on the timeline for filing its New Drug Application (NDA) for the approval of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results